[
  {
    "sentence": "Safety analyses were summarized descriptively.Multiple-dose administration\nStudy design\nA multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Mean duration of ESRD and of chronic HD was similar across groups.PK analyses\nSingle-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The relationship between total clearance (CL) and renal function (represented by eGFR) shows that CL is directly correlated with renal function (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Summary statistics were rounded to 3 significant figures\n*PK parameters for day 1 are for the first dose; steady-state PK parameters for day 5 are for the third dose\nAUC0-44, area under the plasma concentration-time curve from time 0 to 44 h; AUCtau, area under the plasma concentration-time curve over the dosing interval (approximately 48 h for the first dose on day 1 and 72 h for the third dose on day 5); CLss, total steady-state clearance; Cmax, maximum plasma concentration; CV, coefficient of variation; Fe, percent dose excreted unchanged in urine; fu, unbound (free) fraction of difelikefalin in plasma; min-max, minimum-maximum; NDD, non–dialysis-dependent; RAC, accumulation ratio based on AUC.; SD, standard deviation; t1/2, terminal elimination half-life; Tmax, time to maximum plasma concentration; Vz, volume of distribution in the terminal elimination phase; λz, the observed elimination rate constant\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Multiple-dose administration: Mean difelikefalin plasma concentration-time profiles for HD subjects from day 1 to day 8 are presented in Fig. 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety analyses were summarized descriptively.Multiple-dose administration\nStudy design\nA multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Mean duration of ESRD and of chronic HD was similar across groups.PK analyses\nSingle-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The relationship between total clearance (CL) and renal function (represented by eGFR) shows that CL is directly correlated with renal function (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Summary statistics were rounded to 3 significant figures\n*PK parameters for day 1 are for the first dose; steady-state PK parameters for day 5 are for the third dose\nAUC0-44, area under the plasma concentration-time curve from time 0 to 44 h; AUCtau, area under the plasma concentration-time curve over the dosing interval (approximately 48 h for the first dose on day 1 and 72 h for the third dose on day 5); CLss, total steady-state clearance; Cmax, maximum plasma concentration; CV, coefficient of variation; Fe, percent dose excreted unchanged in urine; fu, unbound (free) fraction of difelikefalin in plasma; min-max, minimum-maximum; NDD, non–dialysis-dependent; RAC, accumulation ratio based on AUC.; SD, standard deviation; t1/2, terminal elimination half-life; Tmax, time to maximum plasma concentration; Vz, volume of distribution in the terminal elimination phase; λz, the observed elimination rate constant\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Multiple-dose administration: Mean difelikefalin plasma concentration-time profiles for HD subjects from day 1 to day 8 are presented in Fig. 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety analyses were summarized descriptively.Multiple-dose administration\nStudy design\nA multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Mean duration of ESRD and of chronic HD was similar across groups.PK analyses\nSingle-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The relationship between total clearance (CL) and renal function (represented by eGFR) shows that CL is directly correlated with renal function (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Summary statistics were rounded to 3 significant figures\n*PK parameters for day 1 are for the first dose; steady-state PK parameters for day 5 are for the third dose\nAUC0-44, area under the plasma concentration-time curve from time 0 to 44 h; AUCtau, area under the plasma concentration-time curve over the dosing interval (approximately 48 h for the first dose on day 1 and 72 h for the third dose on day 5); CLss, total steady-state clearance; Cmax, maximum plasma concentration; CV, coefficient of variation; Fe, percent dose excreted unchanged in urine; fu, unbound (free) fraction of difelikefalin in plasma; min-max, minimum-maximum; NDD, non–dialysis-dependent; RAC, accumulation ratio based on AUC.; SD, standard deviation; t1/2, terminal elimination half-life; Tmax, time to maximum plasma concentration; Vz, volume of distribution in the terminal elimination phase; λz, the observed elimination rate constant\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Multiple-dose administration: Mean difelikefalin plasma concentration-time profiles for HD subjects from day 1 to day 8 are presented in Fig. 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety analyses were summarized descriptively.Multiple-dose administration\nStudy design\nA multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Mean duration of ESRD and of chronic HD was similar across groups.PK analyses\nSingle-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The relationship between total clearance (CL) and renal function (represented by eGFR) shows that CL is directly correlated with renal function (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Summary statistics were rounded to 3 significant figures\n*PK parameters for day 1 are for the first dose; steady-state PK parameters for day 5 are for the third dose\nAUC0-44, area under the plasma concentration-time curve from time 0 to 44 h; AUCtau, area under the plasma concentration-time curve over the dosing interval (approximately 48 h for the first dose on day 1 and 72 h for the third dose on day 5); CLss, total steady-state clearance; Cmax, maximum plasma concentration; CV, coefficient of variation; Fe, percent dose excreted unchanged in urine; fu, unbound (free) fraction of difelikefalin in plasma; min-max, minimum-maximum; NDD, non–dialysis-dependent; RAC, accumulation ratio based on AUC.; SD, standard deviation; t1/2, terminal elimination half-life; Tmax, time to maximum plasma concentration; Vz, volume of distribution in the terminal elimination phase; λz, the observed elimination rate constant\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Multiple-dose administration: Mean difelikefalin plasma concentration-time profiles for HD subjects from day 1 to day 8 are presented in Fig. 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety analyses were summarized descriptively.Multiple-dose administration\nStudy design\nA multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Mean duration of ESRD and of chronic HD was similar across groups.PK analyses\nSingle-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The relationship between total clearance (CL) and renal function (represented by eGFR) shows that CL is directly correlated with renal function (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Summary statistics were rounded to 3 significant figures\n*PK parameters for day 1 are for the first dose; steady-state PK parameters for day 5 are for the third dose\nAUC0-44, area under the plasma concentration-time curve from time 0 to 44 h; AUCtau, area under the plasma concentration-time curve over the dosing interval (approximately 48 h for the first dose on day 1 and 72 h for the third dose on day 5); CLss, total steady-state clearance; Cmax, maximum plasma concentration; CV, coefficient of variation; Fe, percent dose excreted unchanged in urine; fu, unbound (free) fraction of difelikefalin in plasma; min-max, minimum-maximum; NDD, non–dialysis-dependent; RAC, accumulation ratio based on AUC.; SD, standard deviation; t1/2, terminal elimination half-life; Tmax, time to maximum plasma concentration; Vz, volume of distribution in the terminal elimination phase; λz, the observed elimination rate constant\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Multiple-dose administration: Mean difelikefalin plasma concentration-time profiles for HD subjects from day 1 to day 8 are presented in Fig. 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety analyses were summarized descriptively.Multiple-dose administration\nStudy design\nA multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Mean duration of ESRD and of chronic HD was similar across groups.PK analyses\nSingle-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The relationship between total clearance (CL) and renal function (represented by eGFR) shows that CL is directly correlated with renal function (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Summary statistics were rounded to 3 significant figures\n*PK parameters for day 1 are for the first dose; steady-state PK parameters for day 5 are for the third dose\nAUC0-44, area under the plasma concentration-time curve from time 0 to 44 h; AUCtau, area under the plasma concentration-time curve over the dosing interval (approximately 48 h for the first dose on day 1 and 72 h for the third dose on day 5); CLss, total steady-state clearance; Cmax, maximum plasma concentration; CV, coefficient of variation; Fe, percent dose excreted unchanged in urine; fu, unbound (free) fraction of difelikefalin in plasma; min-max, minimum-maximum; NDD, non–dialysis-dependent; RAC, accumulation ratio based on AUC.; SD, standard deviation; t1/2, terminal elimination half-life; Tmax, time to maximum plasma concentration; Vz, volume of distribution in the terminal elimination phase; λz, the observed elimination rate constant\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Multiple-dose administration: Mean difelikefalin plasma concentration-time profiles for HD subjects from day 1 to day 8 are presented in Fig. 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety analyses were summarized descriptively.Multiple-dose administration\nStudy design\nA multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Mean duration of ESRD and of chronic HD was similar across groups.PK analyses\nSingle-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The relationship between total clearance (CL) and renal function (represented by eGFR) shows that CL is directly correlated with renal function (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Summary statistics were rounded to 3 significant figures\n*PK parameters for day 1 are for the first dose; steady-state PK parameters for day 5 are for the third dose\nAUC0-44, area under the plasma concentration-time curve from time 0 to 44 h; AUCtau, area under the plasma concentration-time curve over the dosing interval (approximately 48 h for the first dose on day 1 and 72 h for the third dose on day 5); CLss, total steady-state clearance; Cmax, maximum plasma concentration; CV, coefficient of variation; Fe, percent dose excreted unchanged in urine; fu, unbound (free) fraction of difelikefalin in plasma; min-max, minimum-maximum; NDD, non–dialysis-dependent; RAC, accumulation ratio based on AUC.; SD, standard deviation; t1/2, terminal elimination half-life; Tmax, time to maximum plasma concentration; Vz, volume of distribution in the terminal elimination phase; λz, the observed elimination rate constant\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Multiple-dose administration: Mean difelikefalin plasma concentration-time profiles for HD subjects from day 1 to day 8 are presented in Fig. 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety analyses were summarized descriptively.Multiple-dose administration\nStudy design\nA multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Mean duration of ESRD and of chronic HD was similar across groups.PK analyses\nSingle-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The relationship between total clearance (CL) and renal function (represented by eGFR) shows that CL is directly correlated with renal function (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Summary statistics were rounded to 3 significant figures\n*PK parameters for day 1 are for the first dose; steady-state PK parameters for day 5 are for the third dose\nAUC0-44, area under the plasma concentration-time curve from time 0 to 44 h; AUCtau, area under the plasma concentration-time curve over the dosing interval (approximately 48 h for the first dose on day 1 and 72 h for the third dose on day 5); CLss, total steady-state clearance; Cmax, maximum plasma concentration; CV, coefficient of variation; Fe, percent dose excreted unchanged in urine; fu, unbound (free) fraction of difelikefalin in plasma; min-max, minimum-maximum; NDD, non–dialysis-dependent; RAC, accumulation ratio based on AUC.; SD, standard deviation; t1/2, terminal elimination half-life; Tmax, time to maximum plasma concentration; Vz, volume of distribution in the terminal elimination phase; λz, the observed elimination rate constant\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Multiple-dose administration: Mean difelikefalin plasma concentration-time profiles for HD subjects from day 1 to day 8 are presented in Fig. 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Safety analyses were summarized descriptively.Multiple-dose administration\nStudy design\nA multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Multiple-dose administration\nStudy design\nA multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Study design\nA multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A multiple-dose, randomized, double-blind, placebo-controlled, 2-part phase 2 study (NCT02229929, first registration: 03/09/2014) with ESRD subjects undergoing HD was conducted at 20 sites in the United States from July 2014 through study completion in July 2015 (Fig. 1; Part A [PK and safety]: single site; note that Part B of this study did not include PK assessments and is not described in this report).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Mean duration of ESRD and of chronic HD was similar across groups.PK analyses\nSingle-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The relationship between total clearance (CL) and renal function (represented by eGFR) shows that CL is directly correlated with renal function (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Summary statistics were rounded to 3 significant figures\n*PK parameters for day 1 are for the first dose; steady-state PK parameters for day 5 are for the third dose\nAUC0-44, area under the plasma concentration-time curve from time 0 to 44 h; AUCtau, area under the plasma concentration-time curve over the dosing interval (approximately 48 h for the first dose on day 1 and 72 h for the third dose on day 5); CLss, total steady-state clearance; Cmax, maximum plasma concentration; CV, coefficient of variation; Fe, percent dose excreted unchanged in urine; fu, unbound (free) fraction of difelikefalin in plasma; min-max, minimum-maximum; NDD, non–dialysis-dependent; RAC, accumulation ratio based on AUC.; SD, standard deviation; t1/2, terminal elimination half-life; Tmax, time to maximum plasma concentration; Vz, volume of distribution in the terminal elimination phase; λz, the observed elimination rate constant\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Multiple-dose administration: Mean difelikefalin plasma concentration-time profiles for HD subjects from day 1 to day 8 are presented in Fig. 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "PK analyses\nSingle-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The relationship between total clearance (CL) and renal function (represented by eGFR) shows that CL is directly correlated with renal function (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Summary statistics were rounded to 3 significant figures\n*PK parameters for day 1 are for the first dose; steady-state PK parameters for day 5 are for the third dose\nAUC0-44, area under the plasma concentration-time curve from time 0 to 44 h; AUCtau, area under the plasma concentration-time curve over the dosing interval (approximately 48 h for the first dose on day 1 and 72 h for the third dose on day 5); CLss, total steady-state clearance; Cmax, maximum plasma concentration; CV, coefficient of variation; Fe, percent dose excreted unchanged in urine; fu, unbound (free) fraction of difelikefalin in plasma; min-max, minimum-maximum; NDD, non–dialysis-dependent; RAC, accumulation ratio based on AUC.; SD, standard deviation; t1/2, terminal elimination half-life; Tmax, time to maximum plasma concentration; Vz, volume of distribution in the terminal elimination phase; λz, the observed elimination rate constant\nFig. 3.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Multiple-dose administration: Mean difelikefalin plasma concentration-time profiles for HD subjects from day 1 to day 8 are presented in Fig. 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Single-dose administration: After single IV doses of difelikefalin, mean plasma difelikefalin exposure generally increased with increasing severity of renal impairment (Fig. 2A and B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The relationship between total clearance (CL) and renal function (represented by eGFR) shows that CL is directly correlated with renal function (Fig. 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Multiple-dose administration: Mean difelikefalin plasma concentration-time profiles for HD subjects from day 1 to day 8 are presented in Fig. 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  }
]